Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Nivolumab/Ipilimumab Stands as the SOC for MSI-H/dMMR mCRC

April 23rd 2025

Heinz-Josef Lenz, MD, and Van Karlyle Morris, MD, discuss the significance of the FDA approval of nivolumab plus ipilimumab for MSI-H/dMMR mCRC.

Nivolumab/Ipilimumab Establishes Unprecedented Efficacy and Safety Standards in Advanced HCC

April 23rd 2025

Aiwu Ruth He, MD, PhD, discusses data from the CheckMate 9DW trial that supported the FDA approval of frontline nivolumab plus ipilimumab for advanced HCC.

Updated ASCO Living Guidelines Highlight Need for Timely, Patient-Friendly Communication in Stage IV NSCLC

April 23rd 2025

Fawzi F Abu Rous, MD, discusses updates to the ASCO Living Guidelines for the management of stage IV non–small cell lung cancer with driver alterations.

Dr Harrison on Factors Influencing Patient Prognosis and Treatment Selection in Myelofibrosis

April 22nd 2025

Claire Harrison, MD, FRCP, FRCPath, discusses factors informing treatment selection for patients with myelofibrosis.

Mutational Sequencing Evolutions Drive Precision Medicine Approaches for AML

April 22nd 2025

Eunice Wang, MD, provides an overview of currently available AML treatments and highlights the importance of mutational sequencing strategies.

PSMA PET Guides the Individualized Use of Lutetium-Based Therapies in mCRPC

April 22nd 2025

Evan Y. Yu, MD, discusses the clinical evolution of radiopharmaceuticals for patients with mCRPC and how PSMA PET may evolve to monitor treatment response.

Responsible AI Use Ushers in a New Era of Oncology Practice and Patient Care

April 22nd 2025

Douglas Flora, MD, FACCC, LSSBB, discusses the growing role of artificial intelligence tools in oncology practice.

Motivation and Consistency Are Key to Building a Successful Oncology Educational Platform: With Chandler Park, MD; and Paul Hanona, MD

April 21st 2025

In this episode, Drs Park and Hanona give advice to up-and-coming oncology content creators.

Dr Rampal on the Benefits and Limitations of JAK Inhibitors in Myelofibrosis

April 21st 2025

Raajit Rampal, MD, discusses treatment decision-making factors, such as JAK inhibitor efficacy and signs of treatment failure, for myelofibrosis.

Dr Ip on Reasons for Studying Real-World CAR T-Cell Therapy Outcomes in LBCL

April 21st 2025

Andrew Ip, MD, discusses the need for real-world studies investigating the efficacy and safety of CAR T-cell therapy in patients with LBCL.

Fertility and Toxicity Considerations Factor into TNBC Management

April 21st 2025

Nerea Lopetegui-Lia, MD, discusses fertility preservation options for patients with TNBC and considerations for managing treatment-related toxicities.

Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1–Positive mTNBC

April 21st 2025

The combination of sacituzumab govitecan and pembrolizumab improved PFS vs pembrolizumab plus chemotherapy in PD-L1–positive mTNBC.

T-DXd/Pertuzumab Yields PFS Benefit vs THP in HER2+ Metastatic Breast Cancer

April 21st 2025

Frontline T-DXd plus pertuzumab led to statistically significant and clinically meaningful PFS improvements vs THP in HER2+ metastatic breast cancer.

Biomarker Research Aims to Overcome Treatment Challenges in Squamous Cell Carcinoma of the Lung

April 21st 2025

Fawzi F Abu Rous, MD, discusses ongoing efforts to address unmet needs in the management of squamous cell carcinoma of the lung.

Orthopedic Oncology Experts Shape Global Consensus on Chondrosarcoma Management

April 19th 2025

R. Lor Randall, MD, FACS, discusses the importance of orthopedic oncology consensus meetings and the need for agreement about certain surgical practices.

Dr Kaklamani on the Efficacy of Inavolisib in HR+, PIK3CA-Mutated Breast Cancer

April 18th 2025

Virginia Kaklamani, MD, DSc, discusses inavolisib's efficacy in PIK3CA-mutated metastatic breast cancer, as well as the importance of biomarker testing.

ADCs Are Poised to Transform the Metastatic TNBC Treatment Arsenal

April 18th 2025

Nerea Lopetegui-Lia, MD, discusses ongoing trials investigating ADCs that are shaking up the metastatic triple-negative breast cancer setting.

Cyclin E1 Positivity May Enhance Patient Selection for Azenosertib in Platinum-Resistant Ovarian Cancer

April 18th 2025

Fiona Simpkins, MD, discusses the use of cyclin E1 positivity as a biomarker of azenosertib response in platinum-resistant ovarian cancer.

Tarlatamab and Durvalumab Enhance the SCLC Immunotherapy Paradigm

April 18th 2025

Isabel Preeshagul, DO, MBS, discusses frontline treatment selection for patients with SCLC and significant FDA approvals in this disease.

Investigational and Established Biomarkers Guide Ongoing CRPC Therapy Developments

April 18th 2025

Evan Y. Yu, MD, discusses future directions for biomarker research and targeted therapy development for patients with castration-resistant prostate cancer.